



Certificate of analysis

SFC854-03-02

Operator: Satyan Chintawar

Date: 13/08/2015

Supervisor: Zam Cader

Date: 12/02/2016



Signature: *Zam Cader*

Source of fibroblasts and reprogramming information


- SF854 from Oxford University Hospitals, 05/07/2013
- Reprogrammed at UOXF WIMM
- Reprogrammed on 09/10/2014 at passage 4
- Cytotune v2 WP3 SOP10

Viability post-thaw and Morphology according to SOP19 passage 20

- Cell count immediately post-thaw 2.75×10^6
- Viability immediately post-thaw 87.8%
- Photo at 24h & day 4 post-thaw (scale bar = $100\mu\text{m}$):



Sendai clearance: according to WP3 SOP15 undetectable at passage 20



Product sizes: Actin 92bp; SeV 181bp; SeV KOS 528bp; SeV-Myc 532bp; SeV-Klf 410bp;

Mycoplasma Test:

According to MycoAlert Lonza LT07-318 undetectable at passage 20

Sample	Passage Number	Initials	Reading 1	Reading 2	Ratio/Status
+ ve control			54	5829	107.94
- ve control			105	77	0.73
SFC854-03-02	p20	SDC	49	29	0.59

Results mean


Ratio **0 - 0.999** negative for mycoplasma

Ratio **1 – 1.3** Borderline Result (retest required)


Ratio above **1.3** positive for mycoplasma

Flow cytometric analysis according to WP3 SOP 20 and 21 passage 20

Tra-1-60:



NANOG:



SNP analysis

according to WP3 SOP Preparation of DNA and RNA samples for Illumina arrays

- Passage 20
- Identity to parent fibroblasts confirmed
- Karyotype abnormalities: none detected
- For details and raw data see StemDB